13 hours ago
Natco Pharma shares dip 2% after company receives one observation from US FDA following Mekaguda API facility inspection
By Aman Shukla Published on June 16, 2025, 09:33 IST
Natco Pharma shares fell 2% in early trade after the company announced that the U.S. Food and Drug Administration (US FDA) concluded a routine inspection at its API (Active Pharmaceutical Ingredients) facility in Mekaguda, Hyderabad, with one observation. As of 9:32 AM, the shares were trading 2.59% lower at Rs 889.10.
The inspection was carried out over five days, from June 9 to June 13, 2025. In an exchange filing, Natco stated that it received a single Form 483 observation, which it described as procedural in nature. The company expressed confidence in addressing the issue promptly and thoroughly.
'The observation is procedural in nature, and the company is confident of addressing it comprehensively,' Natco said in a statement, reaffirming its commitment to maintaining high compliance standards.
The Mekaguda facility plays a key role in Natco's API production for global markets. The company reiterated its focus on adhering to current Good Manufacturing Practices (cGMP) and continuing the supply of high-quality pharmaceutical products.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
